

CITATION REPORT

List of articles citing

Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial

DOI: 10.1001/jamaoncol.2018.0077
JAMA Oncology, 2018, 4, e180077.

Source: <https://exaly.com/paper-pdf/69399444/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
265	Avelumab: A Review of Its Application in Metastatic Merkel Cell Carcinoma. 2018 , 52, 928-935		7
264	Aktuelle Therapiestrategien beim Merkelzellkarzinom. 2018 , 21, 32-39		
263	Die Checkpointinhibition hT Einzug. 2018 , 66, 834-842		
262	Actualit� et perspectives concernant l'immunoth�rapie en oncologie thoracique. 2018 , 105 Suppl 1, S16-S23		
261	[What's new in oncodermatology?]. 2018 , 145 Suppl 7, VIIS40-VIIS46		1
260	Immunotherapy for Merkel Cell Carcinoma. 2018 , 19, 57		12
259	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. 2018 , 6, 99		73
258	Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. 2018 , 9, 3868		123
257	Merkelzellkarzinom: selten, aber aggressiv. 2018 , 34, 44-51		0
256	Avelumab: A Review in Metastatic Merkel Cell Carcinoma. <i>Targeted Oncology</i> , 2018 , 13, 409-416	5	18
255	Avelumab: is it time to get excited?. 2018 , 18, 815-821		4
254	Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. <i>Targeted Oncology</i> , 2018 , 13, 567-582	5	11
253	Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors. 2019 , 20, 74		9
252	Cutaneous Scapular Lesion in an Elderly Woman. <i>JAMA Oncology</i> , 2019 , 5, 1355-1356	13.4	1
251	Carcinoma a cellule di Merkel: gestione clinica e controversie. 2019 , 20, 127-132		
250	Complete response with neoadjuvant avelumab in Merkel cell carcinoma - A case report. 2019 , 99, 104350		4
249	Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series. 2019 , 7, 170		18

248	Updates on the Systemic Treatment of Advanced Non-melanoma Skin Cancer. <i>Frontiers in Medicine</i> , 2019 , 6, 160	4.9	16
247	Histogenesis of Merkel Cell Carcinoma: A Comprehensive Review. <i>Frontiers in Oncology</i> , 2019 , 9, 451	5.3	27
246	Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. <i>Frontiers in Immunology</i> , 2019 , 10, 1337	8.4	63
245	Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA. 2019 , 17, 733-740		5
244	Delivery rate of patients with advanced gastric cancer to third-line chemotherapy and those patients' characteristics: an analysis in real-world setting. 2019 , 10, 957-964		3
243	Updates on Merkel Cell Carcinoma. 2019 , 37, 489-503		15
242	[Immune checkpoint inhibition in Merkel cell carcinoma]. 2019 , 70, 684-690		3
241	Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma. 2019 , 3, 377-390		9
240	[Update in treatment for Merkel Cell Carcinoma and clinical practice guide]. 2019 , 106, 64-72		1
239	Merkel Cell Carcinoma: Updates on Staging and Management. 2019 , 37, 269-277		21
238	Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. <i>Annals of Oncology</i> , 2019 , 30, 1448-1459	10.3	89
237	Cancer immunotherapy: the art of targeting the tumor immune microenvironment. 2019 , 84, 227-240		34
236	S2k-Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) - Update 2018. 2019 , 17, 562-577		3
235	Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US. 2019 , 11, 349-359		3
234	Molecular and immune targets for Merkel cell carcinoma therapy and prevention. 2019 , 58, 1602-1611		2
233	S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - update 2018. 2019 , 17, 562-576		10
232	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. 2019 , 76, 22-32		131
231	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2019 , 5, 1008-1019	13.4	288

230	PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. 2019 , 15, 1111-1122	102
229	PD-1 (PDCD1) promoter methylation in Merkel cell carcinoma: prognostic relevance and relationship with clinico-pathological parameters. 2019 , 32, 1359-1372	13
228	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. 2019 , 37, 693-702	188
227	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. 2019 , 29, 396-416	37
226	New perspectives in Merkel cell carcinoma. 2019 , 31, 72-83	8
225	In-transit recurrence of Merkel cell carcinoma associated with Bowen's disease: The first reported case successfully treated by avelumab. 2019 , 46, 440-443	
224	Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma. 2019 , 20, 391-407	25
223	Successful immunotherapy and irradiation in a HIV-positive patient with metastatic Merkel cell carcinoma. 2019 , 15, 42-45	5
222	Immunotherapy for skin cancer. 2019 , 31, 465-475	34
221	Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma. 2019 , 24, 1375-1383	16
220	Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. 2019 , 9, 16662	21
219	Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response. 2019 , 4, 1-7	1
218	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy). 2019 , 7, 332	10
217	Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: A single-center experience. 2019 , 98, e17348	15
216	Human CD4 T Cells Specific for Merkel Cell Polyomavirus Localize to Merkel Cell Carcinomas and Target a Required Oncogenic Domain. 2019 , 7, 1727-1739	12
215	Drugs that act on the immune system: Cytokines and monoclonal antibodies. 2019 , 41, 423-433	
214	[Merkel-cell carcinoma]. 2019 , 40, 350-354	4
213	Polyomaviruses of the skin: integrating molecular and clinical advances in an emerging class of viruses. 2019 , 180, 1302-1311	12

212	Product review: avelumab, an anti-PD-L1 antibody. 2019 , 15, 891-908	26
211	Cancer immunotherapy of patients with HIV infection. 2019 , 21, 713-720	11
210	Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. 2019 , 145, 429-443	8
209	SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas. 2020 , 76, 251-264	25
208	Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review. 2020 , 82, 440-459	29
207	The Landmark Series: Non-melanoma Skin Cancers. <i>Annals of Surgical Oncology</i> , 2020 , 27, 22-27	3.1 8
206	Novedades terapéuticas en dermatología. <i>Piel</i> , 2020 , 35, 4-9	0.1
205	Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance. 2020 , 9, 1374-1382	21
204	Contemporary Topics in Radiation Medicine: Skin Cancer. 2020 , 34, 189-203	1
203	Prognostic Impact of MCPyV and TIL Subtyping in Merkel Cell Carcinoma: Evidence from a Large European Cohort of 95 Patients. 2020 , 31, 21-32	13
202	Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?. 2020 , 96, 8-33	47
201	Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. 2020 , 59, 249-256	15
200	Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort. 2020 , 8,	7
199	Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma. 2020 , 8,	5
198	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. 2020 , 130, 110621	3
197	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. 2020 , 23, 101580	10
196	Case of Merkel cell carcinoma in a patient with pre-existing ILD. 2020 , 8,	0
195	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. 2020 , 12,	25

194	Non-Melanoma Skin Cancers: Biological and Clinical Features. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	28
193	Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. 2020 , 12, 1758835920937612		27
192	Single administration of avelumab induced a complete response in thyroid transcription factor 1-positive combined Merkel cell carcinoma. 2020 , 47, 1317-1321		
191	The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary. 2020 , 16, 312-319		9
190	Health-related quality of life trajectory of treatment-naïve patients with Merkel cell carcinoma receiving avelumab. <i>Future Oncology</i> , 2020 , 16, 2089-2099	3.6	1
189	Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments. 2020 , 21, 86		3
188	Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study. 2020 , 8,		3
187	[The use of immune checkpoint inhibitors in routine oncology]. 2020 , 79, 809-817		0
186	Real-world outcomes among US Merkel cell carcinoma patients initiating immune checkpoint inhibitors or chemotherapy. <i>Future Oncology</i> , 2020 , 16, 2521-2536	3.6	4
185	Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy. 2020 , 14, 3625-3649		13
184	Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis. 2020 , 3, e2011809		8
183	Merkel Cell Polyomavirus Small T Antigen Activates Noncanonical NF- κ B Signaling to Promote Tumorigenesis. 2020 , 18, 1623-1637		5
182	An Aggressive Presentation of Merkel Cell Carcinoma: A Case Report. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2020 , 8, 2324709620963714	1.2	1
181	Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. 2020 , 8,		70
180	Immune status and the efficacy of radiotherapy on overall survival for patients with localized Merkel cell carcinoma: An analysis of the National Cancer Database. 2020 , 64, 435-443		4
179	Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with metastatic Merkel cell carcinoma. 2020 , 18, 145		2
178	Scientifically based combination therapies with immuno-oncology checkpoint inhibitors. 2020 , 86, 1711-1725		4
177	Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma. 2020 , 25, 810-817		7

176	Selective reactivation of STING signaling to target Merkel cell carcinoma. 2020 , 117, 13730-13739	15
175	Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts. 2020 , 10, 8867	4
174	Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden. 2020 , 4,	0
173	Neoadjuvant Checkpoint Inhibitor Therapy for Merkel Cell Carcinoma. 2020 , 38, 2471-2475	2
172	Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. 2020 , 13, 457-467	3
171	Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. 2020 , 22, 70	10
170	Cavit�orale, ghiandole salivari: tumori benigni e maligni delle labbra. 2020 , 19, 1-18	
169	Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for Immunotherapy. 2020 , 40, 1-10	11
168	Updates and new perspectives in nonmelanoma skin cancer therapy: highlights from 'Immunotherapy Bridge'. 2020 , 12, 167-174	1
167	Management Recommendations for Merkel Cell Carcinoma-A Danish Perspective. 2020 , 12,	8
166	Avelumab as an Emerging Therapy for Eyelid and Periocular Merkel Cell Carcinoma. 2020 , 60, 91-102	1
165	Landscape of current and future therapies of Merkel cell carcinoma. <i>Dermatologic Therapy</i> , 2020 , 33, e13281	2.2
164	Combining DNA Damage Induction with BCL-2 Inhibition to Enhance Merkel Cell Carcinoma Cytotoxicity. 2020 , 9,	5
163	Immunobiology of Merkel cell carcinoma. 2020 , 32, 114-121	5
162	Durable Response to Carboplatin, Etoposide, Nivolumab, and Ipilimumab in Metastatic High-Grade Neuroendocrine Carcinoma of the Gallbladder. 2020 , 49, e19-e20	2
161	A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8 T cell responses. 2020 , 10, 1047-1060	21
160	Variant morphology and random chromosomal integration of BK polyomavirus in posttransplant urothelial carcinomas. 2020 , 33, 1433-1442	5
159	Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma. 2020 , 26, 2257-2267	18

158	Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 402-408	13.4	56
157	A Therapeutic and Diagnostic Multidisciplinary Pathway for Merkel Cell Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020 , 10, 529	5.3	4
156	Artesunate Affects T Antigen Expression and Survival of Virus-Positive Merkel Cell Carcinoma. 2020 , 12,		9
155	Immune status and the efficacy of adjuvant radiotherapy for patients with localized Merkel cell carcinoma of the head and neck. 2020 , 22, 2009-2016		1
154	Pembrolizumab as first line treatment of Merkel cell carcinoma patients - a case series of patients with various co-morbidities. 2020 , 59, 793-796		3
153	Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies. 2020 , 86, 1690-1702		13
152	Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma. 2020 , 26, 598-607		34
151	Merkel Cell Carcinoma: A 28-Year Experience. 2020 , 163, 364-371		2
150	Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. 2020 , 38, 2476-2487		72
149	Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia. 2020 , 12,		18
148	High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma. 2021 , 184, 319-327		12
147	Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma. 2021 , 84, 312-320		5
146	Current concepts and approaches to merkel cell carcinoma. 2021 , 313, 129-138		5
145	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. 2021 , 27, 713-718		8
144	Molecular Pathogenesis of Merkel Cell Carcinoma. 2021 , 16, 69-91		21
143	The emerging role of immunotherapy for the treatment of sarcoma. 2021 , 123, 730-738		8
142	Merkel cell carcinoma: A review. 2021 , 48, 411-421		12
141	There is still a place for tumour-targeted therapies in Merkel cell carcinoma in the era of immune checkpoint inhibitors. 2021 , 184, 195-197		3

140	Merkel Cell Carcinoma. 2021 , 283-307		
139	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy). 2021 , 19, 13		1
138	Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy. 2021 , 11, 6033-6043		9
137	Avelumab. 2021 , 313-325		
136	Emerging Viral Infections. 2021 , 91-110		0
135	Perspectives of Immunotherapy in Non-Melanoma Skin Cancers. 2021 , 339-354		
134	Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy. <i>Frontiers in Immunology</i> , 2021 , 12, 631483	8.4	2
133	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. 2021 ,		5
132	Immunotherapy for Merkel cell carcinoma. 2021 , 123, 775-781		9
131	What is new in dermatotherapy?. 2021 , 87, 135-143		
130	Improved survival in women versus men with merkel cell carcinoma. 2021 , 84, 321-329		8
129	Antivirals against human polyomaviruses: Leaving no stone unturned. 2021 , 31, e2220		2
128	Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review.. 2022 , 17, 63-70		1
127	Drug Development in Neuroendocrine Tumors: What Is on the Horizon?. 2021 , 22, 43		2
126	Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?. 2021 , 14,		5
125	Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy. 2021 , 13, 213-226		
124	Case Report: Favorable Response to the Tyrosine Kinase Inhibitor Apatinib in Recurrent Merkel Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021 , 11, 625360	5.3	2
123	The role of opioids in cancer response to immunotherapy. 2021 , 19, 119		4

122	Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasia. <i>Future Oncology</i> , 2021 , 17, 1069-1081	3.6	3
121	Merkel-Zell-Karzinom. 2021 , 27, 569-578		0
120	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 562315	5.3	3
119	Checkpoint Inhibitors in Checkmating Rare Cancers. 2021 ,		1
118	"Present and future of immunotherapy in Neuroendocrine Tumors". 2021 , 22, 615-636		4
117	Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. 2021 , 9,		10
116	How we treat Merkel cell carcinoma: within and beyond current guidelines. <i>Future Oncology</i> , 2021 , 17, 1363-1377	3.6	4
115	Immunotherapy in advanced Merkel cell carcinoma: Sydney west cancer network experience. 2021 , 65, 760-767		1
114	Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe. <i>Frontiers in Oncology</i> , 2021 , 11, 672021	5.3	1
113	Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity. 2021 , 185, 627-635		5
112	The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma. 2021 , 147, 2569-2578		0
111	Merkel Cell Polyomavirus Infection Induces an Antiviral Innate Immune Response in Human Dermal Fibroblasts. 2021 , 95, e0221120		3
110	Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
109	Merkel cell carcinoma. e55		0
108	RF- Immunotherapy in Merkel Cell Carcinoma. <i>Actas Dermo-sifiliograficas</i> , 2021 , 112, 553-555	0.5	
107	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy). 2021 , 19, 238		1
106	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. 2021 , 9,		58
105	Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021 , 11, 628324	5.3	0

104	Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. 2021 , 13,		3
103	Extended T-Cell Epitope Landscape in Merkel Cell Polyomavirus Large T and Small T Oncoproteins Identified Uniquely in Patients with Cancer. 2021 ,		0
102	Real-World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR-Merkel. 2021 , 26, e1633-e1643		0
101	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. 2021 , 9,		9
100	Merkel Cell Carcinoma of the Head and Neck: Epidemiology, Pathogenesis, Current State of Treatment and Future Directions. 2021 , 13,		1
99	Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. 2021 , 40, 949-982		17
98	T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
97	Cancer immunotherapy from biology to nanomedicine. 2021 , 336, 410-432		3
96	Immune checkpoint inhibitors for advanced or metastatic basal cell carcinoma: how much evidence do we need?. 2021 , 13, 1293-1304		3
95	Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. 2021 , 11, 17324		4
94	Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors. 2021 , 26, e2002-e2012		1
93	Immunotherapy for Non-melanoma Skin Cancer. 2021 , 23, 125		6
92	Response to combined peptide receptor radionuclide therapy and checkpoint immunotherapy with ipilimumab plus nivolumab in metastatic Merkel cell carcinoma. 2021 ,		4
91	Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review. <i>Frontiers in Immunology</i> , 2021 , 12, 720748	8.4	0
90	Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. 2021 , 5, 3387-3396		4
89	Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?. <i>Frontiers in Oncology</i> , 2021 , 11, 739006	5.3	2
88	The effect of patient sex on the efficacy and safety of anticancer immunotherapy. 2021 , 20, 1535-1544		1
87	Coronavirus disease 2019 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up: A monocentre study. 2021 , 154, 167-174		5

86	Impact of Pharmacists on Identification of Immune Checkpoint Inhibitor Toxicities.		
85	Metabolic Modifications, Inflammation, and Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021 , 11, 703681	2	
84	From Merkel Cell Polyomavirus Infection to Merkel Cell Carcinoma Oncogenesis. 2021 , 12, 739695		5
83	Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. 2021 , 13,		3
82	Adcitmer , a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma. 2021 ,		1
81	Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
80	[Place of radiotherapy in the treatment of cutaneous carcinomas]. 2021 , 25, 593-597		0
79	Efficacy and safety profile of avelumab monotherapy. 2021 , 166, 103464		0
78	Cutaneous Malignancies of the Head and Neck. 2021 , 35, 991-1008		
77	Combinatorial therapy in tumor microenvironment: Where do we stand?. 2021 , 1876, 188585		19
76	Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma. 2021 , 70, 2087-2093		11
75	PD-L1 - inhibitors in neuroendocrine neoplasia: Results from a real-life study. 2021 , 100, e23835		3
74	The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer. 2020 , 34, 495-503		7
73	Upregulation of LAGE3 correlates with prognosis and immune infiltrates in colorectal cancer: A bioinformatic analysis. 2020 , 85, 106599		12
72	Immune checkpoint inhibitors to treat cutaneous malignancies. 2020 , 83, 1239-1253		30
71	Merkel cell carcinoma in Taiwan: A series of 24 cases and literature review. 2019 , 98, e17538		4
70	Advanced Merkel cell carcinoma-A focus on medical drug therapy. <i>Dermatologic Therapy</i> , 2020 , 33, e13675		1
69	Recent advances in Merkel cell carcinoma. 2019 , 8,		7

68	Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review. <i>International Journal of Molecular Sciences</i> , 2020 , 22,	6.3	13
67	Low doses in immunotherapy: Are they effective?. 2019 , 2, 54		4
66	Adverse effects of immuno-oncology drugs-Awareness, diagnosis, and management: A literature review of immune-mediated adverse events. 2019 , 56, S10-S22		3
65	Cutaneous Melanoma and Other Skin Cancers. <i>UNIPA Springer Series</i> , 2021 , 979-1007	0.1	
64	Scientific and clinical developments in Merkel cell carcinoma: A polyomavirus-driven, often-lethal skin cancer. <i>Journal of Dermatological Science</i> , 2021 ,	4.3	1
63	Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study. <i>Targeted Oncology</i> , 2021 , 16, 761-771	5	0
62	Study on the Therapeutic Effect of New Drug Bavencio (Avelumab). <i>Pharmacy Information</i> , 2019 , 08, 56-61	0	
61	Avelumab in the treatment of patients with merkel cell carcinoma: initial results of early access program in Russia. <i>Malignant Tumours</i> , 2019 , 9, 53-58	0.3	1
60	Budosenid Treatment of Avelumab Induced Autoimmune Colitis in Patient With Metastatic Merkel Cell Carcinoma; A Case Report. <i>Clinical Oncology and Research</i> , 2019 , 1-4	0.9	
59	Avelumab, una nueva inmunoterapia para pacientes con carcinoma de células de Merkel metastásico. <i>Piel</i> , 2019 , 34, 518-519	0.1	
58	Cavidad oral, glándulas salivales: tumores benignos y malignos de los labios. <i>EMC - Otorrinolaringología</i> , 2020 , 49, 1-19	0	
57	Avelumab for the treatment of patients with Merkel cell carcinoma. <i>Meditinskiy Sovet</i> , 2020 , 94-100	0.4	
56	FR -Inmunoterapia en el carcinoma de células de Merkel. <i>Actas Dermo-sifiliográficas</i> , 2020 ,	0.5	0
55	Immunotherapies For Cancer, a Promising Cure?. 2020 ,		
54	Merkel Cell Polyomavirus and Human Merkel Cell Carcinoma. <i>Recent Results in Cancer Research</i> , 2021 , 217, 303-323	1.5	1
53	Real-accessible novelties in immunotherapy from the perspective of a medical oncologist working in the Czech Republic. <i>Onkologie (Czech Republic)</i> , 2020 , 14, 199-204	0.1	
52	Immunotherapy in Rare Cancers. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020 , 41, 801-803	0.2	
51	Nichtmelanotische Hauttumoren. 2022 , 415-422		

50	Biomarker-Driven Prognostication in Merkel Cell Carcinoma: A Paradigm for Personalized Therapy. <i>Annals of Surgical Oncology</i> , 2021 , 1	3.1	0
49	Postoperative Radiotherapy in Stage I-III Merkel Cell Carcinoma. <i>Radiotherapy and Oncology</i> , 2021 ,	5.3	0
48	Merkel Cell Carcinoma: An updated review of pathogenesis, diagnosis, and treatment options.. <i>Dermatologic Therapy</i> , 2021 , e15292	2.2	2
47	Immunotherapy of cancer in the era of checkpoint inhibitor. <i>Clinical and Experimental Metastasis</i> , 2021 , 39, 231	4.7	1
46	Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma.. 2022 , 10,		3
45	Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective.. <i>Frontiers in Oncology</i> , 2022 , 12, 780716	5.3	1
44	Immune Checkpoint Inhibitors and Palliative Care at the End of Life: An Irish Multicentre Retrospective Study.. <i>Journal of Palliative Care</i> , 2022 , 8258597221078391	1.8	
43	Advances in Immunology: A Cornerstone in Diagnosis and Therapy of Merkel Cell Carcinoma.. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2022 , 10, 23247096221089492	1.2	1
42	Prognostic Value of Radiotherapy and Chemotherapy in Stage I-III Merkel Cell Carcinoma.. <i>Frontiers in Medicine</i> , 2022 , 9, 845905	4.9	
41	Editorial to the Special Issue on Skin Cancer: The State of the Art.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	
40	Phase 2 single arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi Sarcoma (cKS).. <i>Annals of Oncology</i> , 2022 ,	10.3	1
39	Merkel Cell Carcinoma with Gastric Metastasis, a Rare Presentation: Case Report and Literature Review.. <i>Journal of Gastrointestinal Cancer</i> , 2022 , 1	1.6	
38	Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors.. <i>Future Oncology</i> , 2022 ,	3.6	
37	Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
36	Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.. <i>Health Technology Assessment</i> , 2021 , 25, 1-228	4.4	1
35	Two Clinical Cases of Metastatic Merkel Cell Carcinoma Illustrating Avelumab Tolerability in Elderly Patients. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021 , 42, 599-602	0.2	
34	Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence.. <i>Frontiers in Oncology</i> , 2021 , 11, 734354	5.3	1
33	A Case Report of Leptomeningeal Carcinomatosis Secondary to Recurrent Merkel Cell Carcinoma after Avelumab. 2021 , 25,		0

32	Merkel cell carcinoma of the eyelid and periocular region: A review. <i>Saudi Journal of Ophthalmology</i> , 2021 , 35, 186	0.9	0
31	Unklare Rückenschmerzen bei einer Patientin mit malignem Hauttumor.		
30	Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response. <i>Journal of Clinical Medicine</i> , 2022 , 11, 3364	5.1	0
29	Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid: A Retrospective, Monocentric Study. <i>Frontiers in Immunology</i> , 13,	8.4	1
28	Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors. <i>Hormone and Metabolic Research</i> ,	3.1	
27	Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment. 9,		
26	Targeting tumor microenvironment for breast cancer treatment. 2022 , 249-277		1
25	Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy. 2022 , 12, 2091		1
24	First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study. 12,		0
23	Merkel Cell Carcinoma. 2022 , 347-361		0
22	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. 2022 , 15,		1
21	Targeted Therapy and Immunotherapy in Nonmelanoma Skin Cancer. 2022 ,		0
20	Precision Medicine in Oncology Drug Development. 1-15		0
19	Merkel Cell Carcinoma. 2022 ,		0
18	Das periokuläre Merkel-Zell-Karzinom: Eine Übersicht klinischer Aspekte und aktueller Therapieoptionen.		0
17	Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG. 2022 , 10, e005930		0
16	Management and Prognosis of Cardiac Metastatic Merkel Cell Carcinoma: A Case-Control Study and Literature Review. 2022 , 14, 5914		1
15	Expert Insights on Current Treatments for Hepatocellular Carcinoma: Clinical and Molecular Approaches and Bottlenecks to Progress. Volume 9, 1247-1261		1

14	Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis. 2023 , 15, 84	0
13	Current treatments and emerging therapies of human polyomavirus-associated skin diseases: a comprehensive review.	1
12	Epitheliale Tumore im Kopf-Hals-Bereich. 2022 , 237-261	0
11	Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin CancersEmerging Strategies for Clinical Management. Publish Ahead of Print,	1
10	An update on Merkel cell carcinoma. 2023 , 1878, 188880	0
9	Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors. 2023 , 12, 218	0
8	BRCA1/2 Pathogenic Variants Are Not Common in Merkel Cell Carcinoma: Comprehensive Molecular Study of 30 Cases and Meta-Analysis of the Literature. 2023 ,	0
7	Merkel cell carcinoma: epidemiology, clinical features, diagnosis and treatment of a rare disease. 2023 ,	0
6	Immunotherapy of Merkel Cell Carcinoma. 2023 , 1-22	0
5	Characterization of the Impact of Merkel Cell Polyomavirus-Induced Interferon Signaling on Viral Infection.	0
4	Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinomaA multicenter real-world experience in Israel.	0
3	No abscopal effects of immunotherapy combined with stereotactic radiation therapy in Merkel cell carcinoma.	0
2	Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab. 13,	0
1	Prognostic Biomarker SLCO4A1 Is Correlated with Tumor Immune Infiltration in Colon Adenocarcinoma. 2023 , 2023, 1-13	0